Omnicell agrees to acquire Aesynt for $275M
Omnicell signed a definitive agreement to acquire Aesynt, adding automated dispensing, central pharmacy robotics, IV robotics and analytics to its medication-management portfolio.
Evidence notes
- Deal value: $275 million
- Acquired portfolio included automated dispensing, central pharmacy robotics and IV robotics
- Transaction expanded Omnicell from medication automation into a broader pharmacy robotics platform
Company context
Omnicell supplies medication-management automation, pharmacy robotics, dispensing cabinets and inventory systems for healthcare providers.